Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hamburg/Sharfstein Choice Underscores Public Health, Stricter Oversight

Executive Summary

The White House's appointment of two former health commissioners to run FDA sends a strong message that the agency is refocusing on public health
Advertisement

Related Content

Taylor Is Sharfstein's Temporary Replacement As FDA's Second-In-Command
Taylor Is Sharfstein's Temporary Replacement As FDA's Second-In-Command
Newcomers To White House, FDA Augur Up-Regulation: Top Stories Of 2009
Newcomers To White House, FDA Augur Up-Regulation: Top Stories Of 2009
FDA Tobacco Authority Likely; Foes Contend Move Is Bad For Agency’s Health
FDA Tobacco Authority Likely; Foes Contend Move Is Bad For Agency’s Health
Sharfstein Is Acting FDA Commissioner As Hamburg Awaits Confirmation
Sharfstein Is Acting FDA Commissioner As Hamburg Awaits Confirmation
Hamburg/Sharfstein Appointments Do Not Signal Split Duties At FDA
Hamburg/Sharfstein Appointments Do Not Signal Split Duties At FDA
Advertisement
UsernamePublicRestriction

Register

RS016018

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel